Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

Vaccine

Volumn 28, Issue 52, 2010, Pages 8268-8274

  Treanor, John J ^a   Taylor, David N ^b   Tussey, Lynda ^b   Hay, Christine ^a   Nolan, Carrie ^a   Fitzgerald, Theresa ^a   Liu, Ge ^b   Kavita, Uma ^b   Song, Langzhou ^b   Dark, Irving ^c   Shaw, Alan ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b VaxInnate Corporation   (United States)

^c Cytel Incorporated   (United States)

Author keywords

Clinical trials; Influenza; Vaccine

Indexed keywords

FLAGELLIN; HEMAGGLUTININ; INFLUENZA VACCINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT HEMAGGLUTININ INFLUENZA FLAGELLIN VACCINE; UNCLASSIFIED DRUG; VAX 125;

ADULT; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MALAISE; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SIDE EFFECT; SORE THROAT; SWEATING; SWELLING; VACCINATION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; C-REACTIVE PROTEIN; CYTOKINES; ESCHERICHIA COLI; FEMALE; FLAGELLIN; GENE EXPRESSION; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PLACEBOS; VACCINATION; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 78649741148     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.009     Document Type: Article

References (22)

1. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
3. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. New Engl J Med 2000, 342:232-239. [see comments].
4. Thompson W.W., Comanor L., Shay D.K. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 2006, 194:S82-S91.
5. Coudeville L., Bailleux F., Riche B., Megas F., Andre P., Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol 2010, 10:18.
6. FDA. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines; 2007.
7. Hebert N.D., Zhang J.X., Chen W., Foellmer B., Helenious A. The number and location of glycans on influenza hemagglutinin determine folding and association with calnexin and calreticulin. J Cell Biol 1997, 139:613-623.
8. Klenk H.D., Wagner R., Heuer D., Wolff T. Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res 2002, 2002:73-75.
9. Davis A.R., Bos T., Ueda M., Nayak D.P., Dowbenko D., Compans R. Immune response to human influenza virus hemagglutinin expressed in E. coli. Gene 1983, 21:273-284.
10. Song L., Nakaar V., Kavita U., Price A., Huleatt J., Tang J., et al. Efficacious recombinant influenza vaccine produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One 2008, 3:e2257.
11. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
12. WHO Recommended composition of influenza virus vaccines for use in the 2007-2008 influenza season. Weekly Epidemiol Record 2007, 82:69-76.
13. WHO Recommended composition of influenza virus vaccines for use in the 2008-2009 influenza season. Weekly Epidemiol Record 2008, 83:81-88.
14. Hobson D., Curry R.L., Beare A.S., Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg 1972, 70:767-777.
15. FDA. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines; 2007.
16. Blander J.M., Medzhitov R. Regulation of phagoxome maturation by signals from toll-like receptors. Science 2004, 304:1014-1018.
17. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
18. Wang B.-Z., Quan F.-S., Kang S.-M., Bozja J., Skountzou I., Compans R. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 2008, 82:11813-11823.
19. Song L., Zhang Y., Yun N., Poussard A., Smith J.N., Smith J.K., et al. Superior efficacy of a recombinant flagellin:H5N1 globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 2009, 27:5875-5884.
20. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
21. Black S., Kushner I., Samols D. C-reactive protein. J Biol Chem 2004, 279:48487-48490.
22. Merx S., Zimmer W., Neumaier M., Ahmad-Nejad P. Characterization and functional investigation of single nucleotide polymorphisms (SNPs) in the human TLR5 gene. Hum Mutat 2006, 27:293.